FDA lifts hold on Adolor/GSK's Entereg
This article was originally published in Scrip
Executive Summary
Clinical investigation for Adolorand GlaxoSmithKline's Entereg (alvimopan) can resume after the US FDAlifted its clinical hold on the product in development for chronic opioid bowel dysfunction (OBD), Adolor said.